This archive contains the following articles listed by volume, issue and page number:

Volume 24, 2020 Articles

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jan/Feb 2020 Pg. 4	PreScription: One Size Does Not Fit All! Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 7-12	Primary Engineering Controls in Pharmaceutical Compounding, Part 2: Biosafety Cabinets Author(s): Mulder Kyle
Jan/Feb 2020 Pg. 14-19	How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems Author(s): Vaughn Stacey R, Radwick Allison
Jan/Feb 2020 Pg. 21-27	Performing a United States Pharmacopeia Chapter <800> Compliant Assessment of Risk Author(s): Cabaleiro Joe
Jan/Feb 2020 Pg. 28-29	New and Improved! Author(s): Brunner Scott
Jan/Feb 2020 Pg. 30-36	Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs Author(s): Dillon L R
Jan/Feb 2020 Pg. 38-43	Basics: Excipients Used in Nonsterile Compounding, Part 4: Antioxidants and Chelating Agents Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 44-50	Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 52	Calculations Author(s): Stockton Shelly J
Jan/Feb 2020 Pg. 54	Amiodarone Hydrochloride 5 mg/mL in SyrSpend SF pH4 Cherry Flavored Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 55	Glutamine 250 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 56	Glycopyrrolate 0.2 mg/mL in Methylcellulose 1% and Syrup Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 57	Hydrocortisone 2%, Iodoquinol 1% Metronidazole 10%, and Zinc Oxide 2% in Polyethylene Glycol Ointment Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 58	Isoniazid 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 59	LCD 5%, Salicylic Acid 6% in Clobetasol Propionate 0.05% Ointment Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 60	Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 61	Potassium Chloride 1 mmol/mL in Ora-Sweet SF Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 62	Progesterone 100-mg, Melatonin 1-mg, and L-Theanine 200-mg Slow-Release Capsules Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 63	Venlafaxine 15 mg/mL in Syrup Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 64-68	Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit Author(s): Lardinois Benjamin, Dimitriou Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence M
Jan/Feb 2020 Pg. 69-76	Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Author(s): Marotta James C, Patel Gopesh, Carvalho Maria, Blakeney Samantha
Jan/Feb 2020 Pg. 77-82	Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets Author(s): Jarouche Marian, Ibrahim Martha, Pearson Jarryd, Low Mitchell, Rowe James
Jan/Feb 2020 Pg. 83-85	Compatibility of Melphalan in Iodinated Contrast Media Author(s): Shi Zhanquan, Abruzzo Todd, Wanasathop Apipa, Li S Kevin
Jan/Feb 2020 Pg. 86-87 View Sample	Errata - How to Qualify Container Closure Systems for Intended Use, Part 1 - IJPC 23(6) 454-461 Author(s):
Mar/Apr 2020 Pg. 92	PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 94-96	Low-dose Naltrexone Therapy for Psoriasis Author(s): Weinstock Leonard B, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
Mar/Apr 2020 Pg. 98-102	Compounding Pearls -- Wound Care: Base Selection Author(s): Riepl Mike
Mar/Apr 2020 Pg. 104-108	Low-dose Pilocarpine Spray to Treat Xerostomia Author(s): Zur Eyal
Mar/Apr 2020 Pg. 110-113	A "North Star" for Pharmacy Compounders Author(s): Brunner Scott
Mar/Apr 2020 Pg. 114-118	Basics of Nonsterile Compounding: Excipients Used in Nonsterile Compounding, Part 5: Compounding Using Solvents and Cosolvent Systems Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 121-126	Intravenous Admixture Preparation Considerations, Part 3: Methods and Techniques to Decrease Incompatibilities Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 128	Calculations Author(s): Stockton Shelly J
Mar/Apr 2020 Pg. 130	Acetazolamide 25 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 131	Cholecalciferol 50,000 IU/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 132	Glycopyrrolate 0.2 mg/mL in Ora-Plus:Ora-Sweet (1:1) Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 133	Minocycline Hydrochloride 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 134	Nitrofurantoin 2 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 135	Propylthiouracil 5 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 136	Quinidine Sulfate 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 137	Terbinafine 25 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 138	Topiramate 5 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 139	Valsartan 4 mg/mL in Syrup NF Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 140-147	The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Author(s): Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
Mar/Apr 2020 Pg. 148-155	Comparison of Disintegrant-addition Methods on the Compounding of Orodispersible Tablets Author(s): Mahesparan Vishnu A/L, Bin Abd Razak Fashli Syafiq, Ming Long Chiau, Uddin ABM Helal, Sarker Md Zaidul Islam, Bin Liew Kai
Mar/Apr 2020 Pg. 156-162	Physicochemical Stability of Ternary Mixtures of Sufentanil, Baclofen, and Ropivacaine in Polypropylene Syringes for Intrathecal Analgesia Author(s): Sorrieul Jérémy, Robert Julien, Chapel Fanny, Gossye Thomas, Devys Catherine
Mar/Apr 2020 Pg. 163-167	Feasibility Study of Asthma Cream Author(s): Kuang Andrew
Mar/Apr 2020 Pg. 168-175	Percutaneous Absorption of Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol from ABH Gel Author(s): Dahal Amit, Neupane Rabin, Boddu Sai HS, Renukuntla Jwala, Khupse Rahul, Dudley Richard
May/Jun 2020 Pg. 180	PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>, <797>, and <825>: Part 2 Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 182-186	Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 1 Author(s): Riepl Mike
May/Jun 2020 Pg. 188-193	Compounding Pearls -- Wound Care: Burn Healing, Part 1 Author(s): Riepl Mike
May/Jun 2020 Pg. 194-197	Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Author(s): Hagan John C III, Everett Eric, Chamberlain Tyler
May/Jun 2020 Pg. 198-199	U.S. Food and Drug Administration Takes Aim (Again) at Animal Compounding: Draft Guidance for Industry #256 Lacks Authority, Will Increase Costs, and Put Pets at Risk Author(s): Brunner Scott
May/Jun 2020 Pg. 200-205	Quality Control: Photostability of Compounded Preparations Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 206-212	Basics: Excipients Used in Nonsterile Compounding, Part 6: Compounding with Viscosity-increasing Agents Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 215-220	Sterile Basics: Intravenous Admixture Preparation Considerations, Part 4: Particulates Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 222	Calculations Author(s): Stockton Shelly J
May/Jun 2020 Pg. 224	Baclofen 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 225	Dexamethasone 1 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 226	Diphenylcyclopropenone 0.1% or 3% in Isopropranol Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 227	Ibuprofen 400-mg and Cyclobenzaprine 2.5-mg Capsules Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 228	Monsel's Solution, Gel, and Paste Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 229	Prednisolone 1 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 230	Sildenafil 2.5 mg/mL in Methylcellulose 1%:Syrup (1:1) Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 231	Tetracycline Hydrochloride 25 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 232	Ursodiol 100 mg/mL in Cod Liver Oil, Veterinary Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 233	Venlafaxine 15 mg/mL in Ora-Plus:Ora-Sweet (1:1) Suspension Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 234-237	Comparative Stability Study of Unit-dose Vancomycin Hydrochloride Oral Solutions in Plastic Capped Oral Syringes and Plastic Sealed Dosage Cups Author(s): Brown Stacy, Lewis Paul
May/Jun 2020 Pg. 238-241	Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions Author(s): Wilder Alyson G, Foushee Jaime A, Fox Laura M, Navalle Jordan, Wright Adrienne M, Greer Megan A
May/Jun 2020 Pg. 242-245	Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture Author(s): Ngim Kenley, Patel Jalpa
May/Jun 2020 Pg. 246-251	Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days Author(s): Svirskis Darren, Jaffer Johaina, Agarwal Priyanka, Khan Ayeshah, Kaur Jaskarn, Cheng Alan, Hanning Sara
May/Jun 2020 Pg. 252-262	Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
Jul/Aug 2020 Pg. 268	PreScription: COVID-19 and Compounding Pharmacists Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 270-276	Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
Jul/Aug 2020 Pg. 278-281	Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 2 Author(s): Riepl Mike
Jul/Aug 2020 Pg. 282-285	Compounding Pearls -- Wound Care: Burn Healing, Part 2 Author(s): Riepl Mike
Jul/Aug 2020 Pg. 287-295	Pharmacies on the Frontline: Responding to the COVID-19 Pandemic Author(s): McElhiney Linda F
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Jul/Aug 2020 Pg. 299-303	Quality Control: Rapid Sterility Testing for Compounding Pharmacies Author(s): Taylor Andrew
Jul/Aug 2020 Pg. 305-309	Sterile Basics: Intravenous Admixture Preparation Considerations, Part 5: pH Considerations Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 310	Calculations Author(s): Stockton Shelly J
Jul/Aug 2020 Pg. 312	Benzonatate 50 mg/mL in Ora-Sweet Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 313	Cyclobenzaprine 5-mg/g and Guaifenesin 10-mg/g Transdermal Cream Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 314	Doxepin Hydrochloride 5% in Cetaphil Cream Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 315	Hydrocortisone Hemisuccinate 2 mg/mL or Hydrocortisone Sodium Phosphate 2 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 316	Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 317	Hydroxyzine (Pamoate) 25-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 318	Lisinopril 1 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 319	Lorazepam 1 mg/mL in a Nonaqueous Cosolvent Vehicle Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 320	Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream) Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 321	Tramadol Hydrochloride 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 322-326	Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula Author(s): Hossain Mohammad Faisal, Levesque Dan, Frye John, Rashid Mamoon
Jul/Aug 2020 Pg. 327-336	Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2020 Pg. 337-345	Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis Author(s): Song Guiyun, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S
Jul/Aug 2020 Pg. 346-351	Single Center Experience with Robot Technologies for Sterile Compounding: A Retrospective Review Author(s): Milibari Loay, Cotugno Michael, Belisle Caryn, Rocchio Megan, Patterson Robert F, Chacon Pablo, Fanikos John, Vo Peter
Sep/Oct 2020 Pg. 356	Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams Author(s): Allen Loyd V Jr
Sep/Oct 2020 Pg. 358-364	Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Author(s): Nogales Luis Marcos, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol
Sep/Oct 2020 Pg. 367-369	Topical Cholesterol/Simvastatin Gel for the Treatment of CHILD Syndrome in an Adolescent Author(s): Cho Sung Kyung, Ashworth Lisa Diggs, Goldman Shauna
Sep/Oct 2020 Pg. 371-379	Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
Sep/Oct 2020 Pg. 380-385	Houston, We Have a Study': History-making African Research Relies on a Maverick Texas Pharmaceutical Compounder Author(s): Lovell Nancy
Sep/Oct 2020 Pg. 386-387	An Unconscionable, Unnecessary Fight Author(s): Brunner Scott
Sep/Oct 2020 Pg. 388-395	Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 7: Compounding with Surfactants Author(s): Allen Loyd V Jr
Sep/Oct 2020 Pg. 397-402	Intravenous Admixture Preparation Considerations, Part 6: pH Considerations -- Applications Author(s): Allen Loyd V Jr
Sep/Oct 2020 Pg. 404	Calculations Author(s): Stockton Shelly J, Bui Phi H
Sep/Oct 2020 Pg. 406	Ketamine 60.6-mg/mL, Acepromazine 0.6-mg/mL, and Xylazine 6.67-mg/mL Injection (Vet-Rat and Hamster); Ketamine 6.06-mg/mL, Acepromazine 0.06-mg/mL, and Xylazine 0.667-mg/mL Injection (Vet-Mouse) Author(s): Allen Loyd V Jr
Sep/Oct 2020 Pg. 407	Levofloxacin 50 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2020 Pg. 408-412	Always the Right Dose? Content Uniformity in Over 100 Different Formulations Tested Author(s): Dijkers Eli, Polonini Hudson, de Oliveira Ferreira Anderson
Sep/Oct 2020 Pg. 413-419	Physicochemical Stability of Compounded Allopurinol Suspensions in PCCA Base, SuspendIt Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Le Giang, Morris Tommy C, Graves Richard A
Sep/Oct 2020 Pg. 420-425	Biotin Regulates Colonization and Growth of Candida albicans in the Catheter Lumen During Nutrient Infusions Author(s): Ohara Hiroshi, Matsuzaki Tetsuya, Ochiai Tatsuya, Hayasaka Masataka
Sep/Oct 2020 Pg. 426-433	Efficacy of an Automated Robotic Cleaning Device for Compounding Pharmacies Author(s): Polonini Hudson, Dijkers Eli CF, Ferreira Anderson O, da Silva Sharlene L, Araújo Paulo Victor C, Koulouridas Savvas
Sep/Oct 2020 Pg. 434-438	Evaluation of the Efficacy and Superiority of Different Vial Rubber Closure Disinfection Techniques Author(s): Bjornstad Matthew, Kosinski Tracy, Burlage Robert
Nov/Dec 2020 Pg. 444	PreScription: The NASEM cBHT Report, Part 1 Author(s): Allen Loyd V Jr
Nov/Dec 2020 Pg. 446-448	NASEM Report on Compounded Topical Pain Creams Author(s): Allen Loyd V Jr
Nov/Dec 2020 Pg. 451-458	Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety Author(s): Allen W Chris, Greeson Nicole MH, Mixon William
Nov/Dec 2020 Pg. 460-465	Establishing a Structured Pharmacy Training Program in Sterile Compounding Author(s): Dirbas Muhannad, AbuSara Aseel K, Whiyabi Shatha, Harb Rema, Telfah Shorouq
Nov/Dec 2020 Pg. 466-470	Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 1 Author(s): DeRosa Angela
Nov/Dec 2020 Pg. 473-478	Intravenous Admixture Preparation Considerations, Part 7: Stability Issues Author(s): Allen Loyd V Jr
Nov/Dec 2020 Pg. 480	Calculations Author(s): Drinnon Stephen D, Stockton Shelly J
Nov/Dec 2020 Pg. 482-490	Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Author(s): Teimouri Arezou, Yeung Pollen, Agu Remigius U
Nov/Dec 2020 Pg. 491-500	Analysis of Extemporaneously Compounded Nasal Preparations Prescribed by Latvian Otorhinolaryngologists and General Practitioners and Comparison with German Formulations Author(s): Kiselova Olga, Maurina Baiba, Sidlovska Venta
Nov/Dec 2020 Pg. 501-508	Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing Author(s): Teimouri Arezou, Yeung Pollen, Agu Remigius U
Nov/Dec 2020 Pg. 509-514	Investigation of Filler Effects on the Compounding of Freeze-dried Orodispersible Tablets Containing Annona muricata Extract Author(s): Azman Syahiera Ezzah Noor, Abd Razak Fashli Syafiq, Kamal Wan Hamirul Bahrin Wan, Zheng Gan Kok, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam, Bin Liew Kai
Nov/Dec 2020 Pg. 515-518	Development and Evaluation of an Anti-aging Cosmetic Formulation Exploring Antioxidant Potential of Vitis vinifera L. Author(s): Carneiro Jaqueline, Marques Gonçalves Melissa, Vicente Pereira Airton
Nov/Dec 2020 Pg. 519-527	Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Author(s): Ma Nathan, Perks William, Law Shirley, Iazzetta John, Walker Scott
Nov/Dec 2020 Pg. 527 View Sample	Erratum: IJPC. 2020; 24(4): 327 Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF PH4 Author(s):